Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655667> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W4385655667 endingPage "e85246b7" @default.
- W4385655667 startingPage "e85246b7" @default.
- W4385655667 abstract "Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: A 71-year-old male was diagnosed in November 2018 with Symptomatic Multiple Myeloma. Baseline investigations showed IgG Kappa para-protein of 31 g/L, FISH analysis failed as bone marrow plasma cells <10%. CT PET scan showed a large sternal mass 9x9.7x7 cm, SUV max. of 7.6 with left 8th rib lesion, SUV max of 7.8. He received standard RVD (Revlimid, Velcade and Dexamethasone) regimen for 7 cycles with very good partial response (VGPR). Paraprotein decreased to 3g/l however there was only slight reduction in plasmacytoma size to 9x8.5x4 with SUV max 7.3. He was switched to KRD (Carfilzomib, Revlimid and Dexamethasone) along with radiotherapy to the sternal lesions with very good response biochemically (SPEP, normal pattern) and radiologically (repeat CT PET scan showed no metabolically active disease with no residual mass). He proceeded to ASCT in March 2020.High risk maintenance was commenced with Lenalidomide + Velcade, however, after 4 months he showed radiological relapse. The treatment was switched to DVD (Daratumumab, Velcade and Dexamethasone) with very good partial response. In July 2021, he noticed multiple small lesions about 0.5-1 cm on the abdominal wall. Biopsy confirmed clonal plasma cells in the abdominal wall subcutaneous fat. The lesions were resolved with local radiotherapy. Aims:Methods: In October 2021 shortly after COVID booster vaccine, the abdominal wall lesions markedly increased in size and number making a confluent group of nodules approximately 20cm x 15cm.He was commenced on Belantamab through the compassionate access program in December 2021. After completing 2 cycles, the nodules completely resolved. At the end of June 2022, he exhibited a biochemical relapse and re-imaging showed new sub centimeter Lymphadenopathy, but no recurrence of the abdominal wall lesions. Results: Our patient showed a complete response of extramedullary Myeloma to BELANTAMAB Summary/Conclusion: The extramedullary phase of Myeloma remains a major medical challenge and further studies are required to clarify the role of antibody-drug conjugates.Keywords: Plasma cells, Multiple myeloma" @default.
- W4385655667 created "2023-08-09" @default.
- W4385655667 creator A5027270602 @default.
- W4385655667 creator A5045330640 @default.
- W4385655667 creator A5075525408 @default.
- W4385655667 creator A5077702238 @default.
- W4385655667 creator A5089174227 @default.
- W4385655667 date "2023-08-01" @default.
- W4385655667 modified "2023-09-27" @default.
- W4385655667 title "PB2158: RELAPSING/REFRACTORY ABDOMINAL WALL EXTRA-MEDULLARY PLASMACYTOMAS DEMONSTRATING A RAPID COMPLETE RESPONSE TO BELANTAMAB MAFODOTIN" @default.
- W4385655667 doi "https://doi.org/10.1097/01.hs9.0000975392.85246.b7" @default.
- W4385655667 hasPublicationYear "2023" @default.
- W4385655667 type Work @default.
- W4385655667 citedByCount "0" @default.
- W4385655667 crossrefType "journal-article" @default.
- W4385655667 hasAuthorship W4385655667A5027270602 @default.
- W4385655667 hasAuthorship W4385655667A5045330640 @default.
- W4385655667 hasAuthorship W4385655667A5075525408 @default.
- W4385655667 hasAuthorship W4385655667A5077702238 @default.
- W4385655667 hasAuthorship W4385655667A5089174227 @default.
- W4385655667 hasBestOaLocation W43856556671 @default.
- W4385655667 hasConcept C126322002 @default.
- W4385655667 hasConcept C141071460 @default.
- W4385655667 hasConcept C2776063141 @default.
- W4385655667 hasConcept C2776364478 @default.
- W4385655667 hasConcept C2776694085 @default.
- W4385655667 hasConcept C2778684742 @default.
- W4385655667 hasConcept C2778822529 @default.
- W4385655667 hasConcept C2778964538 @default.
- W4385655667 hasConcept C2780401358 @default.
- W4385655667 hasConcept C2989005 @default.
- W4385655667 hasConcept C71924100 @default.
- W4385655667 hasConceptScore W4385655667C126322002 @default.
- W4385655667 hasConceptScore W4385655667C141071460 @default.
- W4385655667 hasConceptScore W4385655667C2776063141 @default.
- W4385655667 hasConceptScore W4385655667C2776364478 @default.
- W4385655667 hasConceptScore W4385655667C2776694085 @default.
- W4385655667 hasConceptScore W4385655667C2778684742 @default.
- W4385655667 hasConceptScore W4385655667C2778822529 @default.
- W4385655667 hasConceptScore W4385655667C2778964538 @default.
- W4385655667 hasConceptScore W4385655667C2780401358 @default.
- W4385655667 hasConceptScore W4385655667C2989005 @default.
- W4385655667 hasConceptScore W4385655667C71924100 @default.
- W4385655667 hasIssue "S3" @default.
- W4385655667 hasLocation W43856556671 @default.
- W4385655667 hasLocation W43856556672 @default.
- W4385655667 hasOpenAccess W4385655667 @default.
- W4385655667 hasPrimaryLocation W43856556671 @default.
- W4385655667 hasRelatedWork W1576670771 @default.
- W4385655667 hasRelatedWork W1996748901 @default.
- W4385655667 hasRelatedWork W1998625437 @default.
- W4385655667 hasRelatedWork W2074205062 @default.
- W4385655667 hasRelatedWork W2394933873 @default.
- W4385655667 hasRelatedWork W2564869059 @default.
- W4385655667 hasRelatedWork W2592396717 @default.
- W4385655667 hasRelatedWork W2605951469 @default.
- W4385655667 hasRelatedWork W2765526403 @default.
- W4385655667 hasRelatedWork W3127479238 @default.
- W4385655667 hasVolume "7" @default.
- W4385655667 isParatext "false" @default.
- W4385655667 isRetracted "false" @default.
- W4385655667 workType "article" @default.